RecallRadar

FDA Drug recall D-0160-2025

chlorproMAZINE Hydrochloride Tablets, USP, 25 mg, 100-count bottle, RX only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ

On 2025-01-01 the FDA classified a Class II recall of chlorproMAZINE Hydrochloride Tablets, USP, 25 mg, 100-count bottle, RX only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ by Glenmark Pharmaceuticals Usa, citing CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0160-2025
ClassificationClass II
Statusongoing
Initiated2024-12-11
Published2025-01-01
Last updated2026-09-13 11:52 UTC
CompanyGlenmark Pharmaceuticals Usa
DistributionUS

Product

chlorproMAZINE Hydrochloride Tablets, USP, 25 mg, 100-count bottle, RX only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ; Product of India, NDC 68462-862-01

Reason

CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.

Identifiers

ndc68462-861-01
ndc68462-861-10
ndc68462-862-01
ndc68462-862-10
ndc68462-863-01
ndc68462-863-10
ndc68462-864-01
ndc68462-864-10
ndc68462-865-01
ndc68462-865-10
code_infoLot#: 17230133, Exp 12/31/2024

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0160-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.